Chief Executive Officer Kevin has over 28 years of experience in the biotechnology, therapeutics and medical device industries including positions in sales and marketing, business development, regulatory, operations and C-level management. He has negotiated major license, supply and co-development agreements with multinationals for medical devices, diagnostics, natural health product ingredients and pharmaceutical API’s. As a co-founder and chief executive, Kevin successfully started a clinical diagnostics company and led the development of a product from concept to market. He has M&A experience and was a key member of the team that took a Canadian vaccine company public on the TSE in 2001. Since 2008, Kevin has operated his own consulting business helping start-up and early-stage life science companies with strategy, business planning, business development and operational management. Kevin joined TEC Edmonton in 2013 as an Executive-in-Residence and joined Tevosol in January 2016 as full-time CEO.
Dr. Darren Freed is a cardiac surgeon clinician-scientist with an interest in heart and lung failure and novel techniques to treat these conditions. His primary clinical interests are in cardiothoracic transplantation and mechanical circulatory assistance as well as less invasive cardiac surgery. His primary research interests are in ex-vivo organ perfusion, heart transplantation, mechanical circulatory support and the biological basis of myocardial fibrosis. He obtained his MD from the University of Alberta in 1998 and completed his cardiac surgical training at the University of Manitoba where he also obtained a Ph.D in Physiology in 2004. In 2007 he completed a Clinical Fellowship in Cardiothoracic Transplantation and Ventricular Assist Devices at Papworth Hospital in Cambridge, United Kingdom. He is currently an Associate Professor, Division of Cardiac Surgery, Department of Surgery, with cross appointments in the Departments of Physiology and Biomedical Engineering. He is the Director of Research for the Alberta Transplant Institute.
Nels is a Physicist who has 16 years experience in software development, firmware, and electrical engineering. Starting with Testing and Requirements Engineering at Molecular Imaging, he began Firmware Engineering by finding and fixing a bug in the Atomic Force Microscope controller firmware. Nels reviewed the hardware, finding and fixing electrical engineering bugs. He added software development to his firmware expertise, and then learned project management skills. Nels remained with the company following its acquisition by Agilent Technologies and became the responsible engineer for hardware before joining Darren Freed in founding Tevosol, Inc. in January 2015.
David graduated with his JD/MBA degree from the University of Toronto in 2001 and was called to the bar in 2002. In addition to the practice of law, David has co-founded and operated a successful software business and is active in federal politics. The ability to listen, absorb and synthesize facts and information and to break down complex issues to their core components is central to David’s approach to legal issues. He is known amongst his peers and clients for bringing novel approaches to difficult issues and reframing issues to create outside-the-box solutions and opportunities. In addition to business and the practice of law, David volunteers with and supports various non-profit and charitable organizations.
Dr. Jayan Nagendran is a cardiac surgeon clinician-scientist with an interest in end-stage lung disease and lung transplantation. The focus of his lab and clinical research is on the development and advancement of ex-vivo lung perfusion. He attended undergraduate and medical school at the University of Alberta, completing his MD in 2001. He joined the residency program in Cardiac Surgery at the University of Alberta from 2001-2009, and completed a Ph.D in Experimental Medicine during that time (2005-2008). After completing his cardiac surgical residency, Jayan sub-specialized in cardiothoracic transplantation surgery at Stanford University from 2009 to 2011. Dr. Nagendran’s pioneering roles in ex-vivo lung perfusion in Canada includes performing the first portable clinical ex-vivo lung perfusions in Canada. He created the second clinical ex-vivo lung perfusion program in Canada. He is the sole Canadian investigator of the largest international randomized controlled clinical trial examining the efficacy of ex-vivo lung perfusion compared to the standard of care (cold storage), the INSPIRE clinical trial. Dr. Nagendran is an Assistant Professor in the Department of Surgery and the Director of Research for the Division of Cardiac Surgery at the University of Alberta since 2011.
Carolyn has 8 years of management and technology commercialization experience, founding and operating her own business as well as managing small enterprises and technology start-ups. As a consultant with TEC Edmonton, she delivered projects involving market research and strategy, business planning and development, and financing and investments for technology industry clients. She was previously Director of Operations and Strategy for a health technology start-up, where she conducted strategic analyses, developed business plans, obtained funding, implemented project management processes, and secured strategic partnerships with distributors as well as the world’s leading software developer. She has advised on program expansions as well as assisted with designing new business development processes, including new methods, procedures and tools to ensure system wide alignment to business objectives. Carolyn holds a B.Sc. in Kinesiology from the University of Calgary and an MBA from the Haskayne School of Business.